2[1]Gori S,Mosconi AM,Basurtol C,et al.Weekly paclitaxel in metastatic breast cancer patients:a phase Ⅱ study[J].Tumori,2002,88 (6):470 -473.
3[2]Sledge GW,Loehrer PJ,Roth BJ,et al.Cisplatin as firstline therapy for metastatic breast cancer.[J].J clin oncol,1988,6(12):1811-1814.
4[4]Miller AB,Hoogtraten MB,Staquet M,et al.Reporting results of cancer treatment[J].Cancer,1981,47 (1):207-214.
5[5]Wilson WH,Berg SL,Bryant G,et al.Paclitaxel in doxorubicin refractory or mitoxantrone-refractory breast cancer:a phase Ⅰ/Ⅱ trial of 96-hour infusion[J].J Clin Oncol,1994,12(8):1621-1629.
6[6]Sweeney CJ,Zhu J,Sandler AB,et al.Outcome of patients with a performance status of 2 in eastern cooperative oncology group study E1594:a phase Ⅱ trial in patients with me tastatic nonsmall cell lung carcinoma[J].Cancer,2001,92(10):2639-2647.
5SALCH RA,,GRAHAM-POLE J,CASSANO WF,et al.Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoaduvant chemotherapy[].Cancer.1990
6Mintz M B,Sowers R,Brown K M,et al.An expression signature classifies chemotherapy-resistant pediatric osteosarcoma[].Cancer Research.2005
7Ricci MS,Zong WX.Chemotherapeutic approaches for targeting cell death pathways[].The Oncologist.2006
